Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03770260 · MORE INFO

Limitations, agreements, and source contact

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment · Source last updated 2025-06-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
Enrollment was stopped by the drug company during the third dose level of the Dose Escalation Phase. They discontinued clinical trials using pevonedistat. No participants were enrolled to the Dose Expansion Phase.
point Of Contact
email
jmurra33@jhmi.edu
organization
Johns Hopkins University/SKCCC
phone
4439273568
title
Grants Administrative Manager
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
Enrollment was stopped by the drug company during the third dose level of the Dose Escalation Phase. They discontinued clinical trials using pevonedistat. No participants were enrolled to the Dose Expansion Phase.
point Of Contact
email
jmurra33@jhmi.edu
organization
Johns Hopkins University/SKCCC
phone
4439273568
title
Grants Administrative Manager

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice